Alnylam’s givosiran looks approvable on Phase 3 data, says Piper Jaffray

After Alnylam announced the Phase 3 ENVISION trial of givosiran in acute hepatic porphyria patients hit the primary endpoint of reduction in the annualized rate of composite porphyria attacks, Piper Jaffray analyst Edward Tenthoff said he believes the “robust significance across all components” of the primary endpoint should enable approval. Tenthoff, who expects approvals in early 2020, reiterated his Overweight rating and $142 price target on Alnylam shares, which is down $2.58, or 2.93%, to $85.72 in morning trading.
https://thefly.com/landingPageNews.php?id=2875213